Assessment of Safety and Efficacy of IM19 for Recurrent or Refractory (R/R) Non-Hodgkin's Lymphoma(NHL) Patients

This study is testing an experimental CAR-T cell therapy (called IM19) in people with relapsed or treatment-resistant non-Hodgkin's lymphoma whose cancer cells carry a protein called CD19. **You may be eligible if...** - You have non-Hodgkin's lymphoma that has come back or stopped responding to treatment - Your cancer cells are confirmed to be CD19-positive - You have received prior standard treatments - You are 18 or older **You may NOT be eligible if...** - You have lymphoma involving the central nervous system - You have had a bone marrow or stem cell transplant and are experiencing graft-versus-host disease - You have active uncontrolled infections including HIV or hepatitis - You are pregnant or breastfeeding Talk to your doctor to see if this trial is right for you.